Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Amarendra K, Neppalli"'
Autor:
Carolyn C. Jackson, Jordan M. Schecter, Arnob Banerjee, Satish Valluri, Natalie S. Callander, Parameswaran Hari, Yi Lin, Ravi Vij, R. Frank Cornell, Ankit Kansagra, Jennifer Marino, Luciano J. Costa, Ehsan Malek, Hong Tian, Saad Z. Usmani, Shaji Kumar, Mark A. Fiala, Saurabh Chhabra, Thomas Martin, Sundar Jagannath, Yubin Kang, Kelly N. Godby, Jesus G. Berdeja, Michaela Liedtke, Amarendra K. Neppalli
Publikováno v:
Clinical lymphoma, myelomaleukemia. 22(5)
BACKGROUND In the single-arm, phase 1b/2 CARTITUDE-1 study, ciltacabtagene autoleucel (cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) therapy, showed encouraging efficacy in US patients with multiple myeloma (M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c22f211dd366f63751ee918e5c8da504
https://pubmed.ncbi.nlm.nih.gov/34840088
https://pubmed.ncbi.nlm.nih.gov/34840088
Autor:
Michaela Liedtke, Amarendra K. Neppalli, Elizabeth McGehee, Ehsan Malek, Saad Z. Usmani, Robert F. Cornell, Swapna Narayana, Ankit Kansagra, Natalie S. Callander, Elvira Umyarova, Parameswaran Hari, Arjun Lakshman, Ridhi Gupta, Barry Paul, Joshua Mansour, Zhubin Gahvari, Ujjawal H. Gandhi, William Varnado, Alyssa Barnstead, Saurabh Chhabra, Mark A. Fiala, Emma C. Scott, Megan Jagosky, Saranya Kodali, Ravi Vij, Yubin Kang, Kelly N. Godby, Luciano J. Costa, Shaji Kumar
Publikováno v:
Leukemia. 33:2266-2275
The introduction of CD38-targeting monoclonal antibodies (CD38 MoABs), daratumumab and isatuximab, has significantly impacted the management of patients with multiple myeloma (MM). Outcomes of patients with MM refractory to CD38 MoABs have not been d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::578f20b4b94ab5eea695d3fdb5fd3826
https://doi.org/10.1038/s41375-019-0435-7
https://doi.org/10.1038/s41375-019-0435-7
Autor:
Amarendra K. Neppalli, Sagar Lonial, Shaji Kumar, Sundar Jagannath, Jatin P. Shah, Mark A. Fiala, Paul G. Richardson, Joshua Mansour, Megan Jagosky, Ujjawal H. Gandhi, Zhubin Gahvari, Yubin Kang, Kelly N. Godby, Michaela Liedtke, Elizabeth McGehee, Ravi Vij, Xiwen Ma, David S. Siegel, Robert F. Cornell, Barry Paul, Ehsan Malek, William Varnado, Ankit Kansagra, Shijie Tang, Luciano J. Costa, Saad Z. Usmani, Emma C. Scott, Arjun Lakshman, Michael Kauffman, Noa Biran, Ridhi Gupta, Saurabh Chhabra, Saranya Kodali, Natalie S. Callander, Elvira Umyarova, Parameswaran Hari, Sharon Shacham, Ajai Chari
Publikováno v:
American Journal of Hematology. 96
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3851d8db38696c4773272a9e521dfbe8
https://doi.org/10.1002/ajh.26010
https://doi.org/10.1002/ajh.26010
Autor:
Jessica Marini, Erin R. Weeda, Kathy Hogan Edwards, Andy Maldonado, Hamza Hashmi, Amarendra K. Neppalli
Publikováno v:
Blood. 136:31-32
Introduction: Autologous hematopoietic stem cell transplant (aHCT) has become a standard of care for patients with multiple myeloma (MM). Outpatient aHCT with high dose melphalan conditioning has been shown to reduce costs and length of hospital stay
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c095141d5f250976cd8a6a0dc521089
https://doi.org/10.1182/blood-2020-143137
https://doi.org/10.1182/blood-2020-143137
Autor:
Daniel Ogden, Mathew J. Gregoski, Mamatha Mandava, Kristy Martin, Jennifer Joi Jaroscak, Jerry E Squires, Michelle Hudspeth, Amarendra K. Neppalli
Publikováno v:
Transplantation and Cellular Therapy. 27:S179
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0b3109ad2736d881fad307d62e6a600
https://doi.org/10.1016/s2666-6367(21)00221-9
https://doi.org/10.1016/s2666-6367(21)00221-9
Autor:
Christine M. Litwin, Bakos Jonahtan, Shadi Khalil, Alexander Bray, Sandra Ann Mazzoni, Charles S. Greenberg, Georges El Nahas, Amarendra K. Neppalli, James Kalmuk
Publikováno v:
Journal of Clinical Oncology. 38:e19326-e19326
e19326 Background: Serum protein electrophoresis (SPEP) identifies monoclonal proteins associated with plasma cell disorders including multiple myeloma. There are no large prospective studies looking at clinical ordering patterns of SPEPs. This study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b702386a7464efbd549ef48e2602d5f
https://doi.org/10.1200/jco.2020.38.15_suppl.e19326
https://doi.org/10.1200/jco.2020.38.15_suppl.e19326
Autor:
Amarendra K. Neppalli, Joshua Mansour, Alyssa Barnstead, Ravi Vij, Sharon Shacham, Ehsan Malek, William Varnado, Shijie Tang, Ajai Chari, Megan Jagosky, Xiwen Ma, Shaji Kumar, Saranya Kodali, Saad Z. Usmani, Swapna Narayana, Ridhi Gupta, Jatin P. Shah, Yubin Kang, Emma C. Scott, Kelly N. Godby, Robert F. Cornell, Paul G. Richardson, Ankit Kansagra, Noa Biran, Ujjawal H. Gandhi, Elizabeth McGehee, Sundar Jagannath, David S. Siegel, Natalie S. Callander, Elvira Umyarova, Sagar Lonial, Luciano J. Costa, Michael Kauffman, Zhubin Gahvari, Arjun Lakshman, Mark A. Fiala, Hari Parameswaran, Barry Paul, Saurabh Chhabra, Michaela Liedtke
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e115-e116
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::745bf057327b771e5b558743a7bdf8a9
https://doi.org/10.1016/j.clml.2019.09.191
https://doi.org/10.1016/j.clml.2019.09.191
Publikováno v:
Personalized Therapy for Multiple Myeloma ISBN: 9783319618715
Primary plasma cell leukemia (pPCL) is a de novo presentation of an aggressive extramedullary myeloma characterized by circulating plasma cells in peripheral blood. The clonal plasma cells may accumulate genetic aberrations rapidly in a very short pe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02a1508a1acd9d582dfaf91dc7b88e9f
https://doi.org/10.1007/978-3-319-61872-2_7
https://doi.org/10.1007/978-3-319-61872-2_7
Autor:
Saurabh, Chhabra, Sandeep, Jain, Amanda, Fowler, Valeriy, Sedov, Amarendra K, Neppalli, Cynthia A, Schandl, John, Lazarchick
Publikováno v:
Annals of clinical and laboratory science. 47(5)
IgM multiple myeloma (MM) is a rare entity representing approximately 0.5% of all MM. It should be distinguished from malignant neoplasms of B cells with plasmacytic differentiation such as Waldenstrom macroglobulinemia (WM) and marginal zone lymphom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::742a8aa1bfda601c4605b01f1fdc9c33
https://pubmed.ncbi.nlm.nih.gov/29066491
https://pubmed.ncbi.nlm.nih.gov/29066491
Autor:
Mark A. Fiala, Saad Z. Usmani, Jatin J. Shah, Sundar Jagannath, Sagar Lonial, Shijie Tang, Saurabh Chhabra, Yubin Kang, Kelly N. Godby, Luciano J. Costa, Shaji Kumar, Arjun Lakshman, Robert F. Cornell, Paul G. Richardson, Noa Biran, Ehsan Malek, Ajai Chari, David S. Siegel, Michael Kauffman, Xiwen Ma, Amarendra K. Neppalli, Ujjawal H. Gandhi, Sharon Shacham, Natalie S. Callander, Elvira Umyarova, Parameswaran Hari
Publikováno v:
Blood. 134:3125-3125
Introduction: Proteasome inhibitors (PI), immunomodulatory agents (IMiDs) and the CD38 monoclonal antibody daratumumab (dara) have transformed the management of MM, yet eventual refractoriness to these agents seems inevitable. Relapsed and refractory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2666f4f1701fc5cf37e360081f56404e
https://doi.org/10.1182/blood-2019-124991
https://doi.org/10.1182/blood-2019-124991